Sign In
Buy RXRX
$3.52
+0.180 (+5.39%)
At Close: Jun 26, 2026
Down Over 40%, Is Recursion Pharmaceuticals a Buy on the Dip?
05:03am, Thursday, 06'th Mar 2025
Machine-learning techniques keep improving efficiency in one industry after another. One corner of the economy where investors expect another big leap forward is the world of drug development.
Recursion Pharmaceuticals' Update Could Shed Light On Pipeline, Cost-Saving Plans, Analyst Says
11:19am, Monday, 03'rd Mar 2025
Recursion Pharmaceuticals Inc RXRX is a leader in the TechBio space "due to its broad capabilities and extensive internal data generation," according to Needham.
Recursion Pharmaceuticals, Inc. (RXRX) Q4 2024 Earnings Call Transcript
01:16pm, Friday, 28'th Feb 2025
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX ) Q4 2024 Earnings Conference Call February 28, 2025 8:30 AM ET Company Participants Chris Gibson - Co-Founder & Chief Executive Officer Lina Nilsson - Sen
Recursion Pharmaceuticals (RXRX) Reports Q4 Loss, Lags Revenue Estimates
08:41am, Friday, 28'th Feb 2025
Recursion Pharmaceuticals (RXRX) came out with a quarterly loss of $0.53 per share versus the Zacks Consensus Estimate of a loss of $0.36. This compares to loss of $0.40 per share a year ago.
Recursion Provides Business Updates and Reports Fourth Quarter and Fiscal Year 2024 Financial Results
06:30am, Friday, 28'th Feb 2025
SALT LAKE CITY, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, today reported business updates and fin
Recursion to Report Fourth Quarter and Fiscal Year 2024 Business Updates and Financial Results on February 28th
08:00am, Monday, 24'th Feb 2025
Salt Lake City, UT, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, announced today it will provi
Sudden Ascent: Is Recursion Pharmaceuticals NVIDIA's AI Favorite?
08:03am, Friday, 21'st Feb 2025
Recursion Pharmaceuticals' NASDAQ: RXRX stock price has seen a dramatic increase, not due to company-specific news or drug announcements, but rather due to actions taken by artificial intelligence (AI
Altitude Lab Startups Raise $154M in Capital
11:00am, Tuesday, 18'th Feb 2025
The Accelerator Awards $150,000 Fellowship to Elnora AI CEO, and Announces Key Cohort Milestones The Accelerator Awards $150,000 Fellowship to Elnora AI CEO, and Announces Key Cohort Milestones
Recursion Pharmaceuticals Before Q4 Earnings: How to Play the Stock
09:41am, Tuesday, 18'th Feb 2025
RXRX is expected to provide updates on its oncology and rare disease pipeline in its fourth-quarter earnings release, given the absence of a marketed product.
25 Top AI Stocks That Could Boost Your Portfolio
08:30am, Tuesday, 18'th Feb 2025
The artificial intelligence (AI) revolution is reshaping the global economy at an unprecedented pace, with innovations emerging across every sector from healthcare to transportation. As companies race
Why Recursion Pharmaceuticals Stock Is Soaring Today
12:07pm, Friday, 14'th Feb 2025
Shares of Recursion Pharmaceuticals (RXRX 16.12%) had soared by 15.8% as of 12:06 p.m. ET on Friday.
Biotechs on the Brink: 2 Stocks With Huge Potential
07:15am, Friday, 14'th Feb 2025
Investors know the biotech industry is a waiting game—smaller companies in this space often work to secure the funding to keep their doors open during a pre-revenue period while they develop drug tr
Recursion Pharmaceuticals (RXRX) Laps the Stock Market: Here's Why
06:51pm, Thursday, 13'th Feb 2025
In the most recent trading session, Recursion Pharmaceuticals (RXRX) closed at $8.50, indicating a +1.92% shift from the previous trading day.
Recursion: CDK7 Inhibitor Differentiation Is Initially Paying Off
06:05pm, Thursday, 13'th Feb 2025
Company is advancing REC-617, a promising reversible, non-covalent CDK7 inhibitor, showing potential in treating advanced solid tumors with positive interim phase 1 data. The company is also progressi
Recursion Pharmaceuticals (RXRX) Stock Jumps 8.9%: Will It Continue to Soar?
06:21am, Thursday, 13'th Feb 2025
Recursion Pharmaceuticals (RXRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in
